Telomir Pharmaceuticals, Inc. 8-K

What Happened
Telomir Pharmaceuticals, Inc. (TELO) filed an 8‑K reporting that on January 8, 2026 it received a written notice from Nasdaq’s Listing Qualifications Department saying the company is not in compliance with Nasdaq Listing Rule 5620(a), which requires listed companies to hold an annual shareholders’ meeting within 12 months of fiscal year end. The company previously submitted a preliminary proxy on Schedule 14A on November 20, 2025 and had planned to hold its annual meeting on December 30, 2025, subject to SEC review of the proxy. Nasdaq’s notice does not cause an immediate delisting and the company’s shares continue to trade on the Nasdaq Capital Market.

Key Details

• Item reported: 3.01 (Notice of Delisting / Failure to Satisfy Continued Listing Standard).
• Nasdaq notice date: January 8, 2026. Rule cited: Nasdaq Listing Rule 5620(a) (annual meeting requirement).
• Deadline to submit compliance plan to Nasdaq: February 23, 2026.
• Company actions: intends to file a compliance plan timely, communicate with Nasdaq about timing, complete SEC review of the proxy and promptly hold the annual meeting to regain compliance.

Why It Matters
For investors, this is a governance/listing compliance issue — not a financial restatement or operational report — but it can affect market confidence. There is no immediate trading impact or delisting, but failure to satisfy Nasdaq could lead to further proceedings that might affect the stock’s listing status. Watch for (1) the company’s compliance plan filing by February 23, 2026, and (2) the timing and outcome of the annual meeting once the SEC completes its review.